ArticleJournal of substance abuse treatment2019
Evidence-based treatment for opioid use disorders: A national study of methadone dose levels, 2011-2017.
Article in Journal of substance abuse treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Comparison of Medication-Assisted Treatment Options for Opioid Addiction: A Review of the Literature.Journal of addictions nursingPooled it
- The correlation between drug abuse belief, refusal of self-efficacy and drug craving of patients in the treatment of methadone replacement treatment.Frontiers in psychology · 2026Article
- The research examining factors associated with the opioid crisis among urban adults (REFOCUS): a mixed methods study protocol.Frontiers in public health · 2025Article
- Article
- Learning optimal dynamic treatment regimes from longitudinal data.American journal of epidemiology · 2024Article
- Knowledge, experiences, and perceptions of medications for opioid use disorder among Black Kentuckians.Annals of medicine · 2024Article
- Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity.JAMA network open · 2024Article
- "Expected to happen": perspectives on post-release overdose from recently incarcerated people with opioid use disorder.Harm reduction journal · 2024Article
- The effect of a pilot brief educational intervention on preferences regarding treatments for opioid use disorder.Drug and alcohol dependence reports · 2024Article
- Identifying the Heterogeneity in the Association between Workforce Diversity and Retention in Opioid Treatment among Black clients.Research square · 2024Article
- Adoption of Electronic Health Record Among Substance Use Disorder Treatment Programs: Nationwide Cross-Sectional Survey Study.Journal of medical Internet research · 2023Article
- Racial, Ethnic, and Sex Differences in Methadone-Involved Overdose Deaths Before and After the US Federal Policy Change Expanding Take-home Methadone Doses.JAMA health forum · 2023Article
- Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.JAMA network open · 2023Article
- Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone.Drug and alcohol dependence reports · 2023Article
- Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder.Drug and alcohol dependence · 2022Article
- A bifurcated opioid treatment system and widening insidious disparities.Addictive behaviors · 2022Article
- Group versus individual treatment for substance use disorders: a study protocol for the COMDAT trial.BMC public health · 2021Article
- Global opioid agonist treatment: a review of clinical practices by country.Addiction (Abingdon, England) · 2020Review
- Patient-centered care's relationship with substance use disorder treatment utilization.Journal of substance abuse treatment · 2020Article
- Opioid-related overdose deaths among African Americans: Implications for research, practice and policy.Drug and alcohol review · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The nation's methadone maintenance treatment (MMT) programs play a central role in addressing the current opioid epidemic. Considerable evidence documents the treatment effectiveness of MMT and, in turn, the importance of adequate dosing to MMT's effectiveness. Yet, as recently as 2011, 41% of patients received doses below the level of 80 mg/day. Using survey data from a nationally representative sample of MMT programs in 2011 and 2017, we examine (1) the extent to which the nation's MMT programs are meeting evidence-based standards for methadone dose level and (2) characteristics of MMT programs that are associated with variation in performance. Our results show that 43% of MMT patients receive <80 mg/day in 2017, and 23% of methadone maintenance patients receive daily doses below 60 mg. Results from multivariate regression analysis of the 2017 survey data show that private for-profit and public organizations significantly under-dosed patients compared to private nonprofit providers. Under-dosing also was more common in programs that serve high proportions of African-American patients. These results are concerning because MMT remains the medication of choice for vulnerable patients with the most severe opioid use disorders, and for-profit providers treat a growing proportion of MMT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.